| Terrence James Callinan, MD | |
|
Silver Street, Connecticut Valley Hospital, Middletown, CT 06457 | |
| (860) 262-5867 | |
| (860) 262-5850 |
| Full Name | Terrence James Callinan |
|---|---|
| Gender | Male |
| Speciality | Psychiatry & Neurology - Psychiatry |
| Location | Silver Street, Middletown, Connecticut |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104985415 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 028500 (Connecticut) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Terrence James Callinan, MD Po Box 351 Silver Street, Connecticut Valley Hospital, Middletown, CT 06457 Ph: (860) 262-5867 | Terrence James Callinan, MD Silver Street, Connecticut Valley Hospital, Middletown, CT 06457 Ph: (860) 262-5867 |
News Archive
Americans spend $25 billion a year on dietary supplement products such as herbs and other botanicals. While the Nutrition Business Journal forecasts that sales of botanical dietary supplements will increase by about 19 percent over the next five years, scientists still don't know the precise properties that make certain plants helpful or harmful to humans. Now, with a new $7.5 million grant from the National Institutes of Health, University of Missouri researchers have created a National Botanical Research Center to answer these questions.
Researchers at the National Institutes of Health in Bethesda, Maryland, have shown how certain synthetic nanobodies bind to the agent that causes coronavirus disease 2019 (COVID-19) – a development that could help inform the design of therapies.
Survivors of sepsis-a life-threatening response to an infection-have expressed a need for advocacy and follow-up support, according to a study authored by professors at the University of Tennessee, Knoxville, and the University of Tennessee Health Science Center in Memphis, and published in Dimensions of Critical Care Nursing.
Eisai Inc. announced today the results of its Phase 3 trial (Study 309), which showed that eribulin met the study's primary endpoint evaluating overall survival in patients who had advanced leiomyosarcoma (LMS) or adipocytic sarcoma (ADI), two types of advanced soft tissue sarcoma.
› Verified 8 days ago
Richard M. Ketai, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 103 S Main St, Middletown, CT 06457 Phone: 860-358-8760 Fax: 860-358-8754 | |
Dr. Carlos A Cardoso, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: Silver Street, Connecticut Valley Hospital, Middletown, CT 06457 Phone: 860-262-5867 Fax: 860-262-5850 | |
Dr. Zachary Malcolm Lenane, MD, MPH Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 70 Holmes Dr, Middletown, CT 06457 Phone: 860-262-5400 | |
Jeffrey H. Gottlieb, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 28 Crescent St, Middletown, CT 06457 Phone: 860-344-6760 Fax: 860-358-4829 | |
Paul Sadowitz, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 635 Main St, Middletown, CT 06457 Phone: 860-347-6971 Fax: 860-638-6601 | |
Dr. Emily A Laurenzano, D.O. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 1250 Silver St, Middletown, CT 06457 Phone: 877-577-3233 | |
Ronald E Johnson, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: Connecticut Valley Hospital, Middletown, CT 06457 Phone: 860-262-5867 Fax: 860-262-5850 |